Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug:29:98-100.
doi: 10.1016/j.preghy.2022.06.008. Epub 2022 Jul 2.

The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

Michael S Tanner  1 , Deborah de Guingand  2 , Maya Reddy  3 , Saskia Rowson  2 , Daniel L Rolnik  3 , Mary-Ann Davey  2 , Ben W Mol  2 , Euan M Wallace  2 , Fabricio Da Silva Costa  4 , Kirsten R Palmer  3
Affiliations

The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia

Michael S Tanner et al. Pregnancy Hypertens. 2022 Aug.

Abstract

Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.

Keywords: Angiogenic; Comorbidities; PlGF; Placental growth factor; Preeclampsia; Soluble fms-like tyrosine kinase-1; sFLT-1.

PubMed Disclaimer

Substances

LinkOut - more resources